Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Treatment with OADs (Oral Anti-Diabetic Drugs) for more than 6 months~* Ongoing stable treatment with metformin for at least 2 months~* Ongoing stable treatment with minimum half maximal dose of any insulin secretagogue for at least 2 months~* Insulin naive~* HbA1c (glycosylated haemoglobin A1c) between 7.0% and 11.0% (inclusive of both values)~Exclusion Criteria:~* Metformin contraindication according to local practice~* TZD (thiazolidinedione) treatment for the last 5 months before trial start~* Systemic treatment with any corticosteroid 3 months before trial start~* Any disease or condition which according to the Investigator would interfere with the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIAsp 30 (Type: EXPERIMENTAL): None
- Glargine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).